Stoke Therapeutics (STOK) FCF Margin (2022 - 2026)
Stoke Therapeutics' quarterly FCF Margin came in at 977.94% in Q1 2026, down 106098.0% year-on-year from N/an in Q1 2025, and up 55.04% quarter-over-quarter from 2175.32% in Q4 2025.
Stoke Therapeutics has reported FCF Margin for 5 years, with the latest figure at 977.94% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 106098.0% year-over-year to 977.94%; the trailing twelve-month figure through Mar 2026 stood at 459.75% (down 49607.0% YoY), and the FY2025 full-year result was 24.46%, up 26221.0% from the prior year.
- FCF Margin for Q1 2026 stood at 977.94%, up from 2175.32% in the prior quarter.
- The five-year high for FCF Margin was 1055.0% in Q1 2022, with the low at 2175.32% in Q4 2025.
- Average FCF Margin over 5 years is 513.66%, with a median of 533.4% recorded in 2023.
- Peak annual rise in FCF Margin reached 66587 bps in 2025, while the deepest fall reached 207320 bps in 2025.
- Tracing STOK's FCF Margin over 5 years: stood at 793.42% in 2022, then gained by 6 bps to 745.11% in 2023, then soared by 86 bps to 102.12% in 2024, then tumbled by 2030 bps to 2175.32% in 2025, then jumped by 55 bps to 977.94% in 2026.
- The last three FCF Margin figures came in at 977.94% (Q1 2026), 2175.32% (Q4 2025), and 289.25% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -977.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -977.94% |
| Dec 31, 2025 | -2,175.32% |
| Sep 30, 2025 | -289.25% |
| Jun 30, 2025 | -183.26% |
| Mar 31, 2025 | 83.04% |
| Dec 31, 2024 | -102.12% |
| Sep 30, 2024 | -444.95% |
| Jun 30, 2024 | -361.64% |
| Mar 31, 2024 | -582.83% |
| Dec 31, 2023 | -745.11% |
| Sep 30, 2023 | -533.40% |
| Jun 30, 2023 | -897.18% |
| Mar 31, 2023 | -425.10% |
| Dec 31, 2022 | -793.42% |
| Sep 30, 2022 | -720.79% |
| Jun 30, 2022 | -637.88% |
| Mar 31, 2022 | 1,055.00% |